Most common grade 3 or higher treatment emergent AEs, select AEs, and other safety data for enrolled patients
| Safety outcome summaries . | N = 39 . | |
|---|---|---|
| n . | % . | |
| Grade ≥3 treatment emergent AEs in >10% patients | ||
| Hypophosphatemia | 9 | 23.1 |
| Neutrophil count decreased | 9 | 23.1 |
| Hypertension | 5 | 12.8 |
| Syncope | 5 | 12.8 |
| Hyperglycemia | 4 | 10.3 |
| Platelet count decreased | 4 | 10.3 |
| Other specific AEs | ||
| COVID-19 infection | 11 | 28.2 |
| Other infections (any grade) | 23 | 59.0 |
| Thromboembolic events | 3 | 7.7 |
| Dose reductions during induction | ||
| ≥1 dose reduction of carfilzomib | 10 | 25.6 |
| ≥1 dose reduction of lenalidomide | 9 | 23.1 |
| ≥1 dose reduction of dexamethasone | 8 | 20.5 |
| Safety outcome summaries . | N = 39 . | |
|---|---|---|
| n . | % . | |
| Grade ≥3 treatment emergent AEs in >10% patients | ||
| Hypophosphatemia | 9 | 23.1 |
| Neutrophil count decreased | 9 | 23.1 |
| Hypertension | 5 | 12.8 |
| Syncope | 5 | 12.8 |
| Hyperglycemia | 4 | 10.3 |
| Platelet count decreased | 4 | 10.3 |
| Other specific AEs | ||
| COVID-19 infection | 11 | 28.2 |
| Other infections (any grade) | 23 | 59.0 |
| Thromboembolic events | 3 | 7.7 |
| Dose reductions during induction | ||
| ≥1 dose reduction of carfilzomib | 10 | 25.6 |
| ≥1 dose reduction of lenalidomide | 9 | 23.1 |
| ≥1 dose reduction of dexamethasone | 8 | 20.5 |
Data refer to AE that occurred in >10% of N = 39 participants.